CraniUS Therapeutics Appoints Johnson & Johnson Senior Executive to Board of Directors
CraniUS Therapeutics Closes $20M Series B Round
Listen to Dr. Chad Gordon, Founder of CraniUS Therapeutics, on the State of MedTech Podcast
CraniUS Awarded Maryland Tech Council’s “2025 Emerging Life Sciences Company of the Year”
CraniUS at LSI
Brain Computing Interfaces Market Growth and Outlet 2023-2033
The NeuroPASS device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies, and any information provided is subject to change as research progresses.
CAUTION: Investigational Device. Limited by Federal (or United States) law to investigational use.
© Copyright 2026 | CraniUS
